Bellevue Life Sciences AcquiBLACU
13F holders, Q3 2024 (September 30)3holders +1
1new positions
0sold out
$10.83avg. 13F price*
At the end of Q3 2024, 3 institutions reported holding Bellevue Life Sciences Acqui (BLACU) in their 13F filings, up 1 from Q2 2024. 1 opened new positions and 0 sold out. The largest holders were Clear Street LLC ($46K), UBS Group AG ($5K) and Tower Research Capital LLC (TRC) ($110).
- Company
- Bellevue Life Sciences Acqui
- CUSIP
- 079174207
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $5K |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 967 shares bought, net +967 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Clear Street LLC | 0.00% | Add +12.6% | 4,179 | $46K |
| UBS Group AG | 0.00% | New | 500 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | No change | 10 | $110 |
"% of holder's portfolio" is BLACU's weight in each manager's 13F, not the share of Bellevue Life Sciences Acqui the manager owns.